- CancerNetwork.com
- CureToday.com
- OncLive.com
- TargetedOnc.com
- Privacy
- Terms & Conditions
- Do Not Sell My Information
© 2022 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
Genitourinary Cancer
Niraparib, Abiraterone, and Prednisone Triplet Shows Efficacy, Safety in mCRPC With HRR Gene Alterations
May 19, 2022
Article
The combination of PARP inhibition and androgen receptor targeted therapy was found to be tolerable in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Patients With Advanced Prostate Cancer on Relugolix Experience Manageable Toxicity Levels
May 18, 2022
Article
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, demonstrated a manageable toxicity profile for patients with advanced prostate cancer.
Patients With Metastatic Urothelial Carcinoma Achieve Superior Survival After Experiencing irAEs With Pembrolizumab
May 17, 2022
Article
In patients receiving immune checkpoint inhibition to treat their metastatic urothelial carcinoma, immune-related adverse effects may serve as a prognostic marker for progression-free and overall survival.
Regardless of Prior Local Treatment, Patients With mHSPC Achieve Improved Long-Term Survival With Enzalutamide Plus ADT
May 16, 2022
Article
A post-hoc analysis of the phase 3 ARCHES found enzalutamide plus androgen deprivation therapy to be an effective treatment for patients with metastatic hormone-sensitive prostate cancer, no matter their history of prior local therapy.
Vitamin C Increases Chemotherapy Responses in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer
May 16, 2022
Article
Patients with locally advanced muscle invasive bladder cancer may experience superior benefit from gemcitabine and carboplatin if the chemotherapy is co-administered with vitamin c.
Cabozantinib/Nivolumab Showcases Clinical Benefit in Papillary Non–Clear Cell RCC
May 13, 2022
Article
Phase 2 trial findings indicate that cabozantinib plus nivolumab may be effective in treating patients with non-clear cell renal cell carcinoma with papillary histology.
Following ADT, Older Patients With Prostate Cancer Are at an Increased Risk of Cardiac Complications
May 08, 2022
Article
Older men who have received androgen-deprivation therapy are an increased risk of heart issues, however, the root of the risk is still not well understood.
Niraparib Showcases Improved Health-Related QOL, Reduced Pain Burden in mCRPC
May 05, 2022
Article
Niraparib improved or maintained health-related quality of life, pain intensity, and pain interference in patients with advanced or metastatic castration-resistant prostate cancer.
FDA Launches Priority Review of Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer
May 04, 2022
Article
The FDA has granted a priority review designation to darolutamide plus docetaxel for patients with metastatic hormone-sensitive prostate cancer.
Apalutamide Does Not Impact Patient-Reported Side Effect Burden, HRQOL in mCSPC
May 02, 2022
Article
The addition of apalutamide to androgen deprivation therapy does not lead to a significant patient-reported side effect burden nor a reduction in health-related quality of life in patients with metastatic castration-sensitive prostate cancer.